148
Views
1
CrossRef citations to date
0
Altmetric
Original Research

Comparison analysis of separate and joint models in case of time-to-death event of HIV/AIDS patients under ART follow-up

Pages 25-33 | Published online: 23 Oct 2018

References

  • Henderson R, Diggle P, Dobson A. Joint modeling of longitudinal measurements and event time data. Biostatistics. 2000;4:465–480.
  • Wu L, Liu W, Yi GY, Huang Y. Analysis of longitudinal and survival data: joint modeling, inference methods, and issues. J Probab Stat. 2012;2012(3):1–17.
  • Tsiatis AA, Davidian M. Joint modeling of longitudinal and time-to-event data: An overview. Stat Sin. 2004;14(3):809–834.
  • Yu M, Law NJ, Taylor JM, Sandler HM. Joint longitudinal-survival-cure models and their application to prostate cancer. Stat Sin. 2004;14(3):835–862.
  • Tseng Y-K, Hsieh F, Wang J-L. Joint modelling of accelerated failure time and longitudinal data. Biometrika. 2005;92(3):587–603.
  • Hatfield LA, Hodges JS, Carlin BP. Joint models: When are treatment estimates improved? Statistics and Its Interface. 2014;7(4):439–453.
  • Zhou J, Zhao X, Sun L. A new inference approach for joint models of longitudinal data with informative observation and censoring times. Stat Sin. 2013;23:571–593.
  • Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Stat. 2004;58(1):16–24.
  • Farewell VT, Prentice RL. A study of distribution shape in life testing. Technometerics. 1979;19:69–75.
  • Bennett S. Log-logistic regression models for survival data. Appl Stat. 1983;32(2):165–171.
  • Guo X, Carlin BP. Separate and joint modeling of longitudinal and event time data using standard computer packages. Am Stat. 2004;58(1):16–24.
  • Robert CP. The Bayesian Choice: From Decision-Theoretic Foundations to Computational Implementation. 2nd ed. Springer LLC; 2007:373–376.
  • Spiegelhalter D, Thomas A, Best N, Lunn D. WinBUGS Version 1.4 User Manual; 2003. Available from: http://www.mrc-bsu.cam.ac.uk/bugs/winbugs/manual14.pdf. Accessed January, 2003.
  • Byers RH, Morgan WM, Darrow WW, et al. Estimating AIDS infection rates in the San Francisco cohort. AIDS. 1988;2(3):207–210.
  • Laurent C, Ngom Gueye NF, Ndour CT, et al. Long-term benefits of highly active antiretroviral therapy in Senegalese HIV-1-infected adults. J Acquir Immune Defic Syndr. 2005;38(1):14–17.
  • Severe P, Leger P, Charles M, et al. Antiretroviral therapy in a thousand patients with AIDS in Haiti. N Engl J Med. 2005;353(22):2325–2334.
  • Braitstein P, Brinkhof MW, Dabis F, et al. Mortality of HIV-1-infected patients in the first year of antiretroviral therapy: comparison between low-income and high-income countries. Lancet. 2006;367(9513):817–824.
  • Andinet W, Miguel S. Determinants of survival in adult HIV patients on antiretroviral therapy in Oromia, Ethiopia. Open Access article. Global Health Action. 2010;3:5398.
  • Lawn SD, Myer L, Orrell C, Bekker LG, Wood R. Early mortality among adults accessing a community-based antiretroviral service in South Africa: implications for programme design. AIDS. 2005;19(18):2141–2148.
  • Asfaw A, Ali D, Eticha T, Alemayehu A, Alemayehu M, Kindeya F. CD4 cell count trends after commencement of antiretroviral therapy among HIV-infected patients in Tigray, Northern Ethiopia: a retrospective cross-sectional study. PLoS One. 2015;10(3):e0122583.